 Organophosphorus Compounds
"Organophosphorus Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds that contain phosphorus as an integral part of the molecule. Included under this heading is broad array of synthetic compounds that are used as PESTICIDES and DRUGS.
| Descriptor ID |
D009943
|
| MeSH Number(s) |
D02.705
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Organophosphorus Compounds".
Below are MeSH descriptors whose meaning is more specific than "Organophosphorus Compounds".
This graph shows the total number of publications written about "Organophosphorus Compounds" by people in this website by year, and whether "Organophosphorus Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 2 | 2 | | 2001 | 1 | 0 | 1 | | 2003 | 1 | 1 | 2 | | 2004 | 1 | 0 | 1 | | 2005 | 1 | 1 | 2 | | 2006 | 0 | 3 | 3 | | 2008 | 1 | 1 | 2 | | 2009 | 0 | 2 | 2 | | 2010 | 2 | 0 | 2 | | 2011 | 2 | 2 | 4 | | 2013 | 1 | 1 | 2 | | 2014 | 1 | 0 | 1 | | 2016 | 3 | 0 | 3 | | 2017 | 3 | 1 | 4 | | 2018 | 3 | 1 | 4 | | 2019 | 2 | 2 | 4 | | 2020 | 1 | 6 | 7 | | 2021 | 0 | 3 | 3 | | 2022 | 0 | 5 | 5 | | 2023 | 2 | 0 | 2 | | 2025 | 2 | 1 | 3 | | 2026 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Organophosphorus Compounds" by people in Profiles.
-
Starling AP, Li X, Ames JL, Barrett ES, Bastain TM, Buss C, Dabelea D, Dunlop AL, Ferrara A, Hedderson MM, Herbstman J, Kannan K, Karagas M, O'Connor TG, Oh J, Peterson AK, Romano ME, Sathyanarayana S, Schmidt RJ, Simhan HN, Strakovsky RS, Trasande L, Wadhwa PD, Zhao Q, Bennett DH, Buckley JP. Gestational exposure to organophosphate ester flame retardants and child growth in weight, height, and body mass index at age 2-10 years: the Environmental influences on Child Health Outcomes Program. Environ Res. 2026 Jun 01; 298:124229.
-
Murray KO, Gioscia-Ryan RA, Justice JN, Santos-Parker JR, Bispham NZ, Hutton DA, Darvish S, Miyamoto-Ditmon J, Clayton ZS, Chonchol M, Seals DR, Rossman MJ. Translational studies of chronic supplementation with a mitochondria-targeted antioxidant to improve physical function with ageing. J Physiol. 2026 04; 604(7):2898-2922.
-
Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries MJ, Zhang P, Rivera VM, Gettinger S. Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer. 2025 Nov; 26(7):e503-e513.e11.
-
Young KA, Hosseini M, Mistry JJ, Morganti C, Mills TS, Cai X, James BT, Nye GJ, Fournier NR, Voisin V, Chegini A, Schimmer AD, Bader GD, Egan G, Mansour MR, Challen GA, Pietras EM, Fisher-Wellman KH, Ito K, Chan SM, Trowbridge JJ. Elevated mitochondrial membrane potential is a therapeutic vulnerability in Dnmt3a-mutant clonal hematopoiesis. Nat Commun. 2025 Apr 16; 16(1):3306.
-
Camidge DR, Sugawara S, Kondo M, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, Kudou K, Asato T, Hupf B, Vranceanu F, Fram RJ, Ohe Y, Popat S. Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials. Lung Cancer. 2025 Mar; 201:108424.
-
Garcia Campelo MR, Wan Y, Lin HM, Chen T, Shen J, Zhang P, Camidge DR. Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial. Lung Cancer. 2023 11; 185:107376.
-
Paul S, Caruthers MH. Synthesis of Backbone-Modified Morpholino Oligonucleotides Using Phosphoramidite Chemistry. Molecules. 2023 Jul 13; 28(14).
-
Hu Q, Liao Y, Cao J, Fang B, Yun SY, Kinose F, Haura EB, Lawrence HR, Doebele RC, Koomen JM, Rix U. Differential Chemoproteomics Reveals MARK2/3 as Cell Migration-Relevant Targets of the ALK Inhibitor Brigatinib. Chembiochem. 2023 06 01; 24(11):e202200766.
-
Jahanzeb M, Lin HM, Wu Y, Zhang P, Gorritz M, McGuiness CB, Huang WT, Sun K, Chen CC, Camidge DR. Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States. Oncologist. 2022 09 02; 27(9):790-798.
-
Reckamp KL, Lin HM, Cranmer H, Wu Y, Zhang P, Kay S, Walton LJ, Shen J, Popat S, Camidge DR. Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L. Curr Med Res Opin. 2022 09; 38(9):1587-1593.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|